GSK’s new T1 drug fails phase III clinical trial

GlaxoSmithKline says that Otelixizumab, a Type 1 drug currently under development, has failed in a phase III clinical trial. The drug has been in development in partnership with Tolerx, according to a recent article from Reuters.

The drug was designed for people with newly diagnosed diabetes. However, the drug failed to preserve beta cell function. Analysts had modest expectations for the drug after a similar offering from Eli Lilly failed in October. The company said it would continue to explore different dosing regiments. However, a second similar clinical study has been halted.

As reported by Diabetes Newshound

Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).
Sign me up!
Open publication
Buy a Desang kitbag

See our range of kitbags